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Hot-spotAggregation is mediated by local unfolding to allow aggregation ‘‘hot spot(s)’’ to become solvent
exposed and available to associate with a hot spot on another partially unfolded protein. Histori-
cally, the unfolding of either the crystallizable fragment (Fc) or the antigen binding fragment
(Fab) regions of a given monoclonal antibody (MAb) has been implicated in aggregation, with differ-
ing results across different proteins. The present work focuses on separately quantifying the aggre-
gation kinetics of isolated Fc, isolated Fab, and intact MAb as a function of pH under accelerated
(high temperature) conditions. The results show that both Fab and Fc are aggregation prone and
compete within the same MAb.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Monoclonal antibody (MAb or immunoglobulin gamma, IgG)
and MAb-based proteins, such as antigen-binding fragments
(Fab), single-chain variable fragments, and multi-speciﬁc scaffolds
such as antibody-drug conjugates, represent one of the largest
growing class of proteins in the pharmaceutical and biotechnology
industries [1]. One of the major concerns associated with success-
ful delivery of protein therapeutics to patients is non-native aggre-
gates that can form during in vivo expression, puriﬁcation and
processing, as well as upon storage and administration. Aggregates
in formulated therapeutic products can cause unwanted immune
responses and loss of biological activity [2,3]. While most thera-
peutic MAbs are formulated at pH values between 5 and 7 [4],
key processing steps such as viral inactivation and elution from
certain afﬁnity-chromatography resins occur at much more acidic
conditions [5,6].
Non-native aggregation (hereafter simply denoted as aggrega-
tion) denotes any process of forming aggregates that are composed
of proteins that have lost some or all of their native or folded
structure; this often will also be accompanied by an increase ininter-protein beta-sheet structures that help to stabilize the
aggregates [7]. The resulting aggregates are typically irreversible
under the solvent conditions that they form. As a result, one must
control the net aggregation rate in order to minimize aggregate
formation [8].
Monomers within the aggregates are conjectured to ‘‘bind’’ to
one another via ‘‘hot spot’’ sequences that contain relatively large
amounts of hydrophobic amino acids that have a high propensity
to form beta-sheet structures that provide stabilizing inter-protein
hydrogen bonds, by analogy with polypeptide aggregation [9–11].
The exact location or sequence identity of such hydrophobic
‘‘patches’’ or hot spots has been experimentally determined for
many polypeptides [12–15], but only for a few folded proteins
[16–18], and for monoclonal antibodies has only been speculated
upon based on analogies with smaller polypeptide systems
[19–21]. Hydrophobic patches have been identiﬁed on the surface
of some MAbs, and in some cases mutations to those regions have
resulted in reduced aggregation rates [22,23].
As the ‘‘hot spot’’ sequences are expected to be highly hydro-
phobic, they are typically buried within the folded structure of sol-
uble proteins, and thus the partially or fully unfolded monomer
state is the ‘‘reactive’’ one with respect to aggregation. It is difﬁcult
to experimentally determine exactly what stretches of amino acids
constitute the ‘‘hot spot’’ for most folded proteins, because they are
anticipated to be relatively small stretches of sequence [21,19] and
performing exhaustive mutagenesis experiments across the full
Fig. 1. Reduced (R) and non-reduced (NR) SDS–PAGE of the Fab and Fc fragments
prepared from the cleavage of the MAb by Endoproteinase Lys-C followed by size
exclusion puriﬁcation via FPLC.
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antibodies.
The most common strategies to minimize aggregation rates are
either to control key solvent conditions such as pH and temperature
[24,25], or to try to identify the ‘‘hot spots’’ and remove them by
altering those sequences [21,19]. The former is based, at least in
part, on the idea that changing the solvent conditions changes the
conformational stability or unfolding free energy of the monomeric
protein, and this alters the effective concentration or fractional pop-
ulation of the unfolded or partially unfolded species that are most
reactive with respect to aggregation. The latter strategy is moti-
vated by the idea of eliminating or reducing the intrinsic aggrega-
tion propensity of the unfolded or partially unfolded monomer
state [26]. The net or observed rate coefﬁcient for aggregation (kobs)
is therefore proportional to the fraction or population of unfolded
monomers and the intrinsic rate coefﬁcient (kint) that one would
obtain if all monomers were sufﬁciently unfolded to reveal their
aggregation-prone ‘‘hot spot(s)’’ [8].
A human IgG consists of two identical light chains (MW  25
kDa) and two identical heavy chains (MW  50 kDa) held to-
gether by disulﬁde bridges. Four polypeptide chains oligomerize
to form a heterotetramer antibody (MW  150 kDa). Each IgG
heavy chain contains a variable domain (VH), and three conserved
domains: CH1, CH2, and CH3 [27]. An IgG light chain is composed
of a single variable domain (VL) and a single constant domain (CL).
The VH and CH1 domains form heterodimers with the light chain
VL and CL domains to create the Fab (Fragment, antigen binding)
domain. The CH2 and CH3 domains can also be isolated together
as the Fc (Fragment, crystallizable) fragment, with the Fab do-
mains being removed via proteolysis [28,29]. The term monoclo-
nal antibody (MAb) is synonymous with the gamma family of
immunoglobulins or IgGs, and denotes any of the four IgG sub-
classes (IgG1–IgG4).
Previous work with human MAbs has suggested that MAb
aggregation may be mediated primarily by unfolding of the CH2
domain [30–32] or Fab domain [25,33], depending on which
monoclonal antibody was being considered. Computational tools
based on aggregation of small polypeptides have been used to
predict that multiple ‘‘hot spots’’ may be possible in a human
MAb [21,19]. However there is no experimental data to show that
several aggregation hot-spots co-exist in a given monoclonal anti-
body, or that any or all become sufﬁciently exposed upon unfold-
ing so as to drive aggregation on practical time scales. The
present report focuses on the relative conformational stability
and aggregation kinetics of a humanized MAb and its correspond-
ing Fab and Fc fragments at acidic to near-neutral pH conditions
and accelerated (elevated) temperatures. The particular human-
ized MAb was derived from a mouse monoclonal antibody raised
against the extracellular domain of human CD40, which is a
48kDa type I membrane glycoprotein of the TNF receptor super-
family and is expressed on immune cells such as B cells, mono-
cytes, macrophages and dendritic cells as well as on various
other cell types including endothelial cells, epithelial cells (e.g.,
keratinocytes), ﬁbroblasts (e.g., synoviocytes) and platelets [34].
The resulting antibody is referred to simply as MAb in the
remainder of this report.
Conditions were selected such that kint is measureable for
some of the domains/fragments, and could be semi-quantitatively
inferred for the others. This permits a direct experimental compar-
ison of the aggregation rates for intact MAb vs. its fragments, as
well as elucidation of the basis for a switch in aggregation-prone
state with changing pH. To the best of our knowledge this is
the ﬁrst time that all aggregation rates have been shown for the
same MAb, rather than comparing different MAbs or comparing
disparate solution conditions. The results also illustrate the
importance of considering multiple competing species andpathways when attempting to mitigate protein aggregation via
either controlling the solution conditions or utilizing protein engi-
neering to remove ‘‘hot spots’’.
2. Materials and methods
The IgG1 was produced at Boehringer Ingelheim Pharmaceuti-
cals, Inc. Details regarding production of this MAb, Fab and Fc frag-
ments, sample preparation and analysis for aggregation and
unfolding experiments, and biophysical characterization of mono-
meric protein samples are provided in the Supplementary material.
In what follows, MAb is used to denote the particular IgG1 that is
the focus of this report.
3. Results and discussion
Fig. 1 shows illustrative SDS–PAGE results for digested and
puriﬁed MAb fragments. There are clear bands around 47kDa and
58kDa in the non-reduced (NR) SDS–PAGE that represent the Fab
and Fc fragments, respectively, puriﬁed from size exclusion chro-
matography (SEC). Two bands around 27kDa and 20kDa are
observed in reduced (R) SDS–PAGE of the Fab fragment, and
represent heavy chain (HC) and light chain (LC) components of
the Fab fragment. One clear band around 29kDa observed in the
reduced SDS–PAGE of Fc fragment corresponds to the HC from
the Fc fragment. The observed bands in reduced and non-reduced
SDS–PAGE conﬁrm the identity and purity of Fab and Fc fragments
prepared from the cleavage of the MAb by Endoproteinase Lys-C
followed by SEC.
The Fab and Fc fragments, as well as the intact MAb, were each
tested in differential scanning calorimetry (DSC) to compare their
conformational stability and unfolding transition(s). Fig. 2 shows
representative thermograms for each species as a function of tem-
perature (T). The main panel shows the thermal unfolding curves
for intact MAb, and its corresponding Fab and Fc fragments at pH
4 (panel A) and pH 6 (panel B). The intact MAb shows two broad
endotherms (peaks) at pH 4, and a shoulder next to the large peak
at pH 6. The Fab shows a single peak at each pH, while the Fc shows
two peaks. The molar concentration of the Fab was double that of
the Fc, so as to make alignment with the thermogram from the
MAb more straightforward.
Fig. 2. Main panel: DSC curves of the intact MAb (black solid line), Fab fragment
(red dashed line) and Fc fragment (blue dash-dotted line) at (a) pH 4 and (b) pH 6.
Insets: monomer loss as a function of incubation time for the intact MAb (black
open squares), Fab fragment (red solid circles) and Fc fragment (blue solid triangles)
at the same pH as the main panel. The solid lines are ﬁrst-order exponential ﬁts to
interpolate the half-life t50. Incubation temperatures for the insets are (a) 60 C and
(b) 75 C as marked by the vertical black arrows in the main panels. The molar
concentrations for main panels and insets is 13.3 lM for the MAb and Fc-fragment
results, and 26.6 lM for the Fab.
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er-T endotherm for the Fc fragment under similar solution condi-
tions corresponds to unfolding of the CH2 domain, while the
higher-T peak results from unfolding of CH3 domain [28,35,36].
Comparison of the Fc, Fab, and MAb thermograms in Fig. 2 shows
that the large peak for the MAb at both pH values is due to a com-
bination of the Fab peak and the CH3 peak, while the CH2 peak from
the Fc corresponds to the lower-T peak of the MAb thermogram at
pH 4, and the shoulder of the MAb thermogram at pH 6. The over-
lapping of the DSC curve of the MAb with that of the sum of the Fab
and Fc fragments (at equivalent molar conc. to that of the MAb)
indicates that the denaturation temperatures of the Fab and Fc do-
mains are not signiﬁcantly affected by their proximity in the MAb
molecule (see Fig. S2 in Supporting information).
Based on the results from DSC for the Fc fragment, temperatures
were selected for isothermal aggregation time-course measure-
ments. The temperatures were selected so as to lie above the CH2
unfolding transition at a given pH, while also lying as far as possi-
ble below the CH3 unfolding peak temperature (Tm). This allowed
comparison of MAb aggregation kinetics with those of the frag-
ments at a condition where the fraction of unfolded CH2 domains
is essentially 1, while the CH3 domains remain folded. No choice
of temperature satisﬁed these criteria while also lying well below
the Tm value for Fab unfolding. The insets in panels (a) and (b) of
Fig. 2 show monomer loss as a function of incubation time at
60 C, pH 4.0 and 75 C, pH 6.0. The monomer loss proﬁle for the
Fc fragment at 60 C and pH 4.0 superimposes quantitatively with
that for the MAb. The half-life values (t50) and observed aggrega-
tion rate coefﬁcients are indistinguishable within statistical uncer-
tainty. However the monomer loss for the Fab fragment
(t50 = 625 min) is much slower (10-fold larger half-life) than that
for the MAb (t50 = 49.5 min) or Fc (t50 = 50.8 min). These results
indicate that aggregation is mediated by CH2 unfolding at this con-
dition. In contrast, at 75 C and pH 6.0 the aggregation kinetics for
intact MAb (t50 = 2.88 min) show a slightly smaller half-life thanthat for Fab fragment (t50 = 6.74 min), and a much shorter half-life
that than of the Fc fragment (t50 = 44.4 min).
Together, these observations indicate that the aggregation of in-
tact MAb is mediated by unfolding of the CH2 domain at the pH 4
conditions, but not at the pH 6 condition. Furthermore, at pH 6 the
incubation temperature is high enough that all the CH2 domains in
the MAb molecules and Fc fragments are unfolded, but is some-
what below the Tm values for unfolding of the Fab or CH3 domains.
This means that a fraction of the MAbmolecules have unfolded Fab
and/or CH3 domains at this condition, a fraction of the Fc fragments
have unfolded CH3 domains, and a fraction of the Fab fragments are
unfolded. The fraction of molecules with unfolded CH3 domains is
the same for Fc fragments and for MAb molecules, and aggregation
of the Fc is much slower than that of MAb. Therefore, CH3 unfolding
does not mediate aggregation for this MAb at either pH 4 or pH 6.
This indicates that Fab unfolding mediates aggregation at the
pH 6 conditions. It is proposed that the reason the monomer loss
proﬁles do not overlay quantitatively for Fab aggregation and
MAb aggregation at this condition is that the MAb has two
branched Fab ‘‘arms’’, compared to a single Fab ‘‘arm’’ per Fab frag-
ment. As a result, there is a statistically higher chance of MAb mol-
ecules ﬁnding ways to aggregate with each other when compared
to just Fab fragments (a simple model to rationalize this is pro-
vided in Supporting information). Obtaining pure (Fab)2 fragments
was beyond the practical scope of this study, but could be consid-
ered to test this hypothesis in future work.
Previous work showed that aggregation is mediated by CH2
unfolding for some antibodies [30–32], while it is mediated by Fab
unfolding for others [25,33]. To the best of our knowledge this is
the ﬁrst report to show that both Fc and Fab are aggregation-prone
in the same antibody and, furthermore, that the dominant domain
mediating aggregation changes with solution pH for the same pro-
tein. Previous computational work hypothesized that there could
be more than one aggregation ‘‘hot spot’’ in the same molecule,
but that hypothesis was not tested experimentally and all ‘‘hot
spots’’ were predicted to be equally aggregation prone [21,19].
In the analysis above and below, it should be noted that the
‘‘unfolded’’ states for Fc and Fab may have signiﬁcant residual sec-
ondary or tertiary structure, as DSC does not provide information
on whether a given endotherm corresponds to complete loss of
structure for a given domain/region of the protein. Spectroscopic
measurements could in principle aid in this regard, however the
fact that aggregation occurs on the time scales of the measure-
ments makes it impractical to deduce the precise structural nature
of the (partially) unfolded state for aggregation of Fc or Fab frag-
ments, or the intact MAb. By analogy to what has been found for
other aggregation-prone proteins, the ‘‘unfolded’’ state or domain
may or may not retain signiﬁcant residual structure [37–43]. In
the analysis below focused on the different domains, it is unneces-
sary to determine the precise structural details of the unfolded (or
partially unfolded) state, although this is an interesting question
and the focus of future work.
Monomer loss proﬁles were ﬁt to give the observed rate coefﬁ-
cient (kobs) for monomer loss over the ﬁrst half-life for each sample
condition in the insets of Fig. 2. Observed rate coefﬁcients deter-
mined in this way are necessarily a combination of contributions
from the intrinsic rate coefﬁcient, kint – i.e., the value of kobs if all
monomers were unfolded to reveal their aggregation ‘‘hot spots’’
– and the reduction in the net rate of aggregation due to the fact
that only a fraction of monomers are unfolded under most solvent
conditions. Mathematically, kint is related to kobs by the following
relationship [7,8], kobs = (fR)n kint, where fR is the fraction of mono-
mers with an unfolded or partially unfolded ‘‘reactive’’ domain at a
given solvent condition and temperature, and n is a stoichiometric
coefﬁcient that depends on whether aggregation is dominated by
dimerization (n = 2) or other mechanisms [44]. For the purposes
Fig. 3. Schematic depiction of the pH-dependent competition between aggregation
pathways. The top panel illustrates that multiple aggregation-prone ‘‘hot spots’’
exist and can be exposed by unfolding of different domains. The bottom panel
qualitatively illustrates that the relative concentration of unfolded CH2 and Fab
domains changes to different extents as a function of pH. For the present MAb, the
unfolded Fab is more aggregation prone than the unfolded CH2. Under conditions
below the Tm of one or both domains, lowering pH causes a much greater decrease
(increase) in the unfolding free energy (unfolded population) for the CH2 relative to
the Fab. This causes a switch from Fab-mediated to CH2-mediated aggregation at
sufﬁciently acidic pH.
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sults, because in what follows fR either equals 1 (Fc-mediated
aggregation) or is close enough to one for order-of-magnitude
analysis (Fab-mediated aggregation).
Table 1 lists the ﬁtted kobs values with their 95% conﬁdence
intervals from the non-linear regression. The values of the net
charge for the MAb from capillary electrophoresis and sedimenta-
tion velocity analytical ultracentrifugation are also given at each
pH (see Section Capillary Zone Electrophoresis in Supplemental
Material), along with the estimated charge values for Fab and Fc
based on the relative amounts of ionizable residues (D, E, H, K, R)
in each domain. The value of fR for aggregation of the CH2 domain
fragments is essentially 1 for both pH 4 and 6 conditions, based on
the choice of incubation temperatures relative to CH2 Tm values at
each pH. Therefore, kobs = kint is a good approximation for these
conditions, independent of any assumed value for n. To the best
of our knowledge, this is ﬁrst time the intrinsic aggregation rate
coefﬁcients associated with CH2 mediated aggregation have been
reported.
These kint values are many orders of magnitude lower than the
corresponding diffusion-limited dimerization rate coefﬁcient at
this protein concentration (see Supporting information). Interest-
ingly, the value of kint for Fc aggregation is essentially unchanged
in moving from pH 4 to pH 6, suggesting that the reduction of
net charge (Z⁄) by changing pH (cf., Table 1) does not affect the
intrinsic aggregation propensity of the unfolded CH2 domain signif-
icantly. This is perhaps not surprising if aggregation is driven by
burial of hydrophobic regions of the unfolded CH2 domain that
do not lie close to charged amino acids, or simply if the ionic
strength of the solutions here were too high to see signiﬁcant
changes in aggregation rates due to changes in Z⁄.
Determining values for kint at pH 4 and 6 for the Fab domain is
more difﬁcult, as the unfolding transition for the Fab domain is not
fully reversible in DSC at either condition (data not shown). To a
ﬁrst approximation, one can estimate fR for the Fab domain by tak-
ing the fraction of the area of the DSC peak from a baseline temper-
ature up to the incubation temperature for monomer loss kinetics,
and then divide that by the total peak area (see Fig. S1 in Supporting
information). Doing so gives fR = 0.0005 and 0.12 at pH 4 and 6,
respectively. The correct value of n is unknown for Fab aggregation,
but typical values lie between 1.5 and 2 [7,44]. Using this range of
magnitudes for fR for Fab aggregation gives kint values that are
orders of magnitude larger than those for Fc at either pH.
It should be noted that estimating fR from the fractional peak
area in DSC is at best a semi-quantitative measure, because aggre-
gation consumes unfolded monomer irreversibly and does not al-
low folding-unfolding equilibrium to be fully achieved during
DSC. As a result, the values of fR determined in this way are likely
to be overestimates of the true fR values [45,46], and so the values
for kint in Table 1 are only order of magnitude estimates to illustrate
that they are much larger for (partially) unfolded Fab fragments of
this IgG1 than for Fc fragments with unfolded CH2 domains.Table 1
Observed and intrinsic aggregation kinetic rates and net charge of the MAb, Fab and Fc fr
Samples pH 4
kobs (1/M/Sec) kint (1/M/Sec) Z⁄
Intact MAb 34 ± 1 467 ± 19 3.2 ± 0.1
Fab fragment 2.6 ± 0.3 >103b 1.75 ± 0.07a
Fc fragment 27.1 ± 0.8 27.1 ± 0.8 1.41 ± 0.06a
a Calculated by taking the experimental Z⁄ value for MAb and scaling it by the ratio of t
for details.
b Magnitude of fR is 0.001 and n is 1.5–2. It is not reasonable to provide a more accur
DSC.Together, these observations are consistent with the following
semi-quantitative mechanistic description (see Fig. 3). Aggregation
of this IgG1 occurs through a competition of at least two pathways:
one that involves CH2 unfolding, and the other that involves Fab
unfolding. The intrinsic aggregation rates are much higher for the
unfolded Fab domain than for the unfolded CH2 domain, but the
thermodynamics of unfolding are sensitive to pH and are different
for the different domains (cf., Fig 2). As a result, as one changes
solution conditions it is possible to shift from aggregation medi-
ated by unfolding of one domain to that mediated by the other do-
main. Empirically, the unfolding free energy for the CH2 domain is
typically reduced to a much greater extent by moving to acidic pH
than is that for Fab domains [47–49]. As such, it is not surprising in
light of the present analysis that Fc-mediated aggregation would
become important only at sufﬁciently low pH for unfolding of
the CH2 domain to occur much more readily than that for Fab do-
mains. The result is a pH-dependent competition between two
pathways, with the dominant pathway depending on both theagments at pH 4 and 6, reported with standard deviation.
pH 6
kobs (1/M/Sec) kint (1/M/Sec) Z⁄
187 ± 51 6  103 ± 2  103 0.54 ± 0.14
100 ± 4 7.0  103 ± 0.3  103 0.30 ± 0.08a
32 ± 8 32 ± 8 0.24 ± 0.06a
he theoretical net valence for the fragment to that for the intact MAb. See main text
ate estimate of fR when the value is so low because of limits of signal to noise in the
940 H. Wu et al. / FEBS Letters 588 (2014) 936–941intrinsic aggregation rate of a given (partially) unfolded species,
and the effective concentration of that species.
The results above show that if one were able to directly com-
pare the aggregation rates of unfolded Fab vs. Fc with unfolded
CH2 domains in a given experimental condition, the unfolded Fab
species is more aggregation prone for this IgG1. The choice of
temperature and solvent condition helps to control the concentra-
tion of those species, and therefore mediates net aggregation rates.
As one moves to much lower temperatures than those tested here,
it is conceivable that: (i) the identity of the rate-determining step
may change, although the identity of the aggregation-prone con-
formational state or intermediate remains the same (e.g., it may
still involve a conformationally disrupted CH2 domain or Fab);
(ii) the dominant pathway for aggregation may change, and then
the identity of the key aggregation-prone intermediate may also
change.
A change in the rate-determining step (RDS) would alter the net
rates of aggregation, but the identity of the ‘‘reactive’’ monomer
state would not be expected to change since the RDS would still
lie somewhere in the same overall mechanism [50–52]. However,
if an alternative pathway for aggregation becomes the lower
free-energy-barrier pathway at lower temperature (e.g., via
adsorption to air–water or solid–liquid interfaces) [53], then it is
possible that the identity of the key aggregation-prone, partially
unfolded monomer state for a given antibody would switch from
high vs. low temperature. Although beyond the scope of the pres-
ent report, future work will focus on aggregation mechanisms over
a wide temperature range and in the presence of other stresses that
could alter mechanisms/key intermediates.
In terms of the implications of the above results for other mono-
clonal antibodies, one must consider that the Fc is essentially con-
served across all members of the same subclass (e.g., IgG1 in this
case), but the Fab is not. As a result, one could encounter antibodies
with Fab domains that have much higher or lower kint values than
the antibody tested here. While engineering variable regions in the
Fab domain to decrease kint of intact IgG1 molecules could be a
strategy to improve resistance of these molecules to aggregation,
the results here highlight that there is a limit to how effective this
can be. That is, if one lowers kint for Fab domains sufﬁciently far,
eventually kint combined with fR for the Fab domain will fall below
that of the CH2 domain for a given monoclonal antibody. This
argues that improving the intrinsic aggregation propensity of the
unfolded CH2 (and possibly CH3) domains should also be consid-
ered when one seeks to improve aggregation resistance by protein
engineering, as has been done for non-IgG antibodies [23] and for
other proteins [26].
Acknowledgements
The authors thank Boehringer Ingelheim Pharmaceuticals Inc.
for ﬁnancial support and the supply of protein. The funding source
was not involved in: study design; collection, analysis and
interpretation of data; writing of the report; and in the decision
to submit the article for publication.Appendix A. Supplementary data
Supplementary data associated with this article can be found,
in the online version, at http://dx.doi.org/10.1016/j.febslet.2014.
01.051.
References
[1] Carter, P. (2011) Introduction to current and future protein therapeutics: a
protein engineering perspective. Exp. Cell Res. 317, 1261–1269.[2] Braun, A., Kwee, L., Labow, M. and Alsenz, J. (1997) Protein aggregates seem to
play a key role among the parameters inﬂuencing the antigenicity of
interferon alpha (IFN-alpha) in normal and transgenic mice. Pharm. Res. 14,
1472–1478.
[3] Schellekens, H. (2002) Bioequivalence and the immunogenicity of
biopharmaceuticals. Nat. Rev. 1, 457–462.
[4] Goswami, S., Wang, W., Arakawa, T. and Ohtake, S. (2013) Developments and
challenges for mAb-based therapeutics. Antibodies 2, 452–500.
[5] Liu, H., Ma, J., Winter, C. and Bayer, R. (2010) Recovery and puriﬁcation process
development for monoclonal antibody production. mAbs 2, 480–499.
[6] Latypov, R., Hogan, S., Lau, H., Gadgil, H. and Liu, D. (2012) Elucidation of acid-
induced unfolding and aggregation of human immunoglobulin IgG1 and IgG2
Fc. J. Biol. Chem. 287, 1381–1396.
[7] Roberts, C. (2007) Non-native protein aggregation kinetics. Biotechnol. Bioeng.
98, 9237–9238.
[8] Roberts, C. (2003) Kinetics of irreversible protein aggregation: analysis of
extended Lumry-Eyring models and implications for predicting protein shelf
life. J. Phys. Chem. B 107, 1194–1207.
[9] Fink, A. (1998) Protein aggregation: folding aggregates, inclusion bodies and
amyloid. Fold. Des. 3, R9–R23.
[10] Uversky, V. and Fink, A. (2004) Conformational constraints for amyloid
ﬁbrillation: the importance of being unfolded. Biochim. Biophys. Acta 1698,
131–153.
[11] Eisenberg,D. et al. (2006) The structural biologyof protein aggregationdiseases:
fundamental questions and some answers. Acc. Chem. Res. 39, 568–575.
[12] Groot, N., Pallares, I., Avilés, F., Vendrell, J. and Ventura, S. (2005) Prediction of
‘hot spots’ of aggregation in disease-linked polypeptides. BMC Struct. Biol. 5,
18, http://dx.doi.org/10.1186/1472-6807-5-18.
[13] Pawar, A. et al. (2005) Prediction of ‘aggregation-prone’ and ‘aggregation-
susceptible’ regions in proteins associated with neurodegenerative diseases. J.
Mol. Biol. 350, 379–392.
[14] Morimoto, A. et al. (2004) Analysis of the secondary structure of beta-amyloid
(Abeta42) ﬁbrils by systematic proline replacement. J. Biol. Chem. 279, 52781–
52788.
[15] Scrocchi, L. et al. (2003) Identiﬁcation of minimal peptide sequences in the (8–
20) domain of human islet amyloid polypeptide involved in ﬁbrillogenesis. J.
Struct. Biol. 141, 218–227.
[16] Zhang, A. et al. (2010) Molecular level insights into thermally induced alpha-
chymotrypsinogen A amyloid aggregation mechanism and semiﬂexible
protoﬁbril morphology. Biochemistry (Mosc.) 49, 10553–10564.
[17] Giasson, B., Murray, I., Trojanowski, J. and Lee, V. (2001) A hydrophobic stretch
of 12 amino acid residues in the middle of alpha-synuclein is essential for
ﬁlament assembly. J. Biol. Chem. 276, 2380–2386.
[18] Ivanova, M., Sievers, S., Sawaya, M., Wall, J. and Eisenberg, D. (2009) Molecular
basis for insulin ﬁbril assembly. PNAS 106, 18990–18995.
[19] Wang, X., Das, T., Singh, S. and Kumar, S. (2009) Potential aggregation prone
regions in biotherapeutics. mAbs 1, 254–267.
[20] Conchillo-Solé, O. et al. (2007) AGGRESCAN: a server for the prediction and
evaluation of ‘hot spots’ of aggregation in polypeptides. BMC Bioinformatics 8.
[21] Fernandez-Escamilla, A., Rousseau, F., Schymkowitz, J. and Serrano, L. (2004)
Prediction of sequence-dependent and mutational effect on the aggregation of
peptides and proteins. Nat. Biotechnol. 22, 1302–1306.
[22] Rouet, R., Lowe, D. and Christ, D. (2014) Stability engineering of the human
antibody repertoire. FEBS Lett. 588 (2), 269–277.
[23] Wörn, A. and Plückthun, A. (2001) Stability engineering of antibody single-
chain Fv fragments. J. Mol. Biol. 305, 989–1010.
[24] He, F., Hogan, S., Latypov, R., Narhi, L. and Razinkov, V. (2009) High throughput
thermostability screening of monoclonal antibody formulations. J. Pharm. Sci.
99, 1707–1720.
[25] Sahin, E., Grillo, A., Perkins, M. and Roberts, C. (2010) Comparative effects of
pH and ionic strength on protein–protein interactions, unfolding, and
aggregation for IgG1 antibodies. J. Pharm. Sci. 99, 4830–4848.
[26] Sahin, E. et al. (2011) Computational design and biophysical characterization
of aggregation-resistant point mutation for cD cyrstallin illustrate a balance of
conformational stability and intrinsic aggregation propensity. Biochemistry
(Mosc.) 50, 628–639.
[27] Bork, P., Holm, L. and Sander, C. (1994) The immunoglobulin fold, structural
classiﬁcation, sequence patterns and common core. J. Mol. Biol. 242, 309–320.
[28] Demarest, S., Rogers, J. and Hansen, G. (2004) Optimization of the antibody
CH3 domain by residue frequency analysis of IgG sequences. J. Mol. Biol. 335,
41–48.
[29] Gauci, P. and Alderton, M. (2001) Pepsin digestion of antibodies to produce
functional antigen-binding fragments (Fab): a scientiﬁc fantasy. Def. Sci.
Technol. Organ., 1–47. (TR-1189).
[30] Andersen, C., Manno, M., Rischel, C., Thorolfsson, M. and Martorana, V. (2010)
Aggregation of a multidomain protein: a coagulation mechanism governs
aggregation of a model IgG1 antibody under weak thermal stress. Protein Sci.
19, 279–290.
[31] Gong, R. et al. (2009) Engineered human antibody constant domains with
increased stability. J. Biol. Chem. 284, 14203–14210.
[32] Liu, H., Chumasae, C., Gaza-Bulseco, G. and Goedken, E. (2010) Domain-level
stability of an antibody monitored by reduction, differential alkylation, and
mass spectrometry analysis. Anal. Biochem. 400, 244–250.
[33] Brummitt, R. et al. (2011) Nonnative aggregation of an IgG1 antibody in acidic
conditions: part 1. unfolding, colloidal interactions, formation of high-
molecular-weight aggregates. J. Pharm. Sci. 100, 2087–2103.
H. Wu et al. / FEBS Letters 588 (2014) 936–941 941[34] Malmborg, A., Ellmark, P., Borrebaeck, C. and Furebring, C. (2003) Afﬁnity and
epitope proﬁling of mouse anti-CD40 monoclonal antibodies. Scand. J.
Immunol. 57, 517–524.
[35] Souillac, P. (2005) Biophysical characterization of insoluble aggregates of a
multi-domain protein: an insight into the role of the various domains. J.
Pharm. Sci. 94, 2069–2083.
[36] Ionescu, R., Vlasak, J., Price, C. and Kirchmeier, M. (2008) Contribution of
variable domains to the stability of humanized IgG1 monoclonal antibodies. J.
Pharm. Sci. 97, 1414–1426.
[37] Grillo, A. et al. (2001) Conformational origin of the aggregation of recombinant
human factor VIII. Biochemistry (Mosc.) 40, 586–595.
[38] Krishnan, S. et al. (2002) Aggregation of granulocyte colony stimulating factor
under physiological conditions: characterization and thermodynamic
inhibition. Biochemistry (Mosc.) 41, 6422–6431.
[39] Hamarstrom, P. et al. (1999) Structural mapping of an aggregation
nucleation site in a molten globule intermediate. J. Biol. Chem. 274, 32897–
32903.
[40] Lindner, R., Treweek, T. and Carver, J. (2001) The molecular cheaperone alpha-
crystallin is in kinetic competition with aggregation to stabilize a monomeric
molten-globule form of alpha-lactalbumin. Biochem. J. 354, 79–87.
[41] Finke, J., Roy, M., Zimm, B. and Jennings, P. (2000) Aggregation events occur
prior to stable intermediate formation during refolding of interleukin 1beta.
Biochemistry (Mosc.) 39, 575–583.
[42] Khurana, R. et al. (2001) Partially folded intermediates as critical precursors of
light chain amyloid ﬁbrils and amorphous aggregates. Biochemistry (Mosc.)
40, 3525–3535.
[43] Rucker, A. and Creamer, T. (2002) Polyproline II helical structure in protein
unfolded states: lysine peptides revisited. Protein Sci. 11, 980–985.[44] Andrews, J. and Roberts, C. (2007) A Lumry-Eyring nucleation plymerization
model of protein aggregation kinetics: 1. aggregation with pre-equilibrated
unfolding. J. Phys. Chem. B 111, 7897–7913.
[45] Sanchez-Ruiz, J., Lopez-Lacomba, J., Cortijo, M. and Mateo, P. (1988)
Differential scanning calorimetry of the irreversible thermal denaturation of
thermolysin. Biochemistry (Mosc.) 27, 1648–1652.
[46] Sanchez-Ruiz, J. (1992) Theoretical analysis of Lumry-Eyring models in
differential scanning calorimetry. Biophys. J. 61, 921–935.
[47] Buren, N., Rehder, D., Gadgil, H., Matsumura, M. and Jacob, J. (2009)
Elucidation of two major aggregation pathways in an IgG2 antibody. J.
Pharm. Sci. 98, 3013–3030.
[48] Vermeer, A. and Norde, W. (2000) The thermal stability of immunoglobulin:
unfolding and aggregation of a multi-domain protein. Biophys. J. 78, 394–404.
[49] Tischenko, V., Abramov, V. and Zav’yaloov, V. (1998) Investigation of the
cooperative structure of Fc fragments from myeloma immunoglobulin G.
Biochemistry (Mosc.) 37, 5576–5581.
[50] Roberts, C. and Darrington, R. (2003) Irreversible aggregation of recombinant
bovine granulocyte-colony stimulating factor (bG-CSF) and implications for
predicting protein shelf life. J. Pharm. Sci. 92, 1095–1111.
[51] Andrews, J. and Roberts, C. (2007) Non-native aggregation of alpha-
Chymotrypsinogen occurs through nucleation and growth with competing
nucleus sizes and negative activation energies. Biochemistry (Mosc.) 46,
7558–7571.
[52] Weiss IV, W., Young, T. and Roberts, C. (2009) Principles, approaches, and
challenges for predicting protein aggregation rates and shelf life. J. Pharm. Sci.
98, 1246–1277.
[53] Bee, J. et al. (2012) Productionofparticles of therapeutic proteins at the air–water
interface during compression/dilation cycles. Soft Matter 8, 10329–10335.
